Zoe Serefoglou
About
In The Last Decade
Zoe Serefoglou
26 papers receiving 807 citations
Peers
Comparison fields: 5 of 62
- Cancer Research 396
- Oncology 336
- Molecular Biology 241
- Immunology 195
- Hematology 107
Countries citing papers authored by Zoe Serefoglou
This map shows the geographic impact of Zoe Serefoglou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zoe Serefoglou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zoe Serefoglou more than expected).
Fields of papers citing papers by Zoe Serefoglou
This network shows the impact of papers produced by Zoe Serefoglou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zoe Serefoglou. The network helps show where Zoe Serefoglou may publish in the future.
Co-authorship network of co-authors of Zoe Serefoglou
This figure shows the co-authorship network connecting the top 25 collaborators of Zoe Serefoglou. A scholar is included among the top collaborators of Zoe Serefoglou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zoe Serefoglou. Zoe Serefoglou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | Prevalence of thrombosis-related DNA polymorphisms in a healthy Greek population. | 11 |
| 3 | A common 9 bp deletion in the ataxia-telangiectasia-mutated gene is not associated with oral cancer. | 2 |
| 4 | Association of polymorphisms in Tumor Necrosis Factor Alpha and Beta genes with increased risk for oral cancer. | 39 |
| 5 | 38 | |
| 6 | 51 | |
| 7 | 51 | |
| 8 | 57 | |
| 9 | Association of -1171 promoter polymorphism of matrix metalloproteinase-3 with increased risk for oral cancer. | 20 |
| 10 | A DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer. | 29 |
| 11 | Angiotensinogen polymorphism is associated with risk for malignancy but not for oral cancer. | 8 |
| 12 | The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. | 41 |
| 13 | Coagulation-related factors, thrombomodulin and protein Z, are not associated with risk for oral cancer. | 4 |
| 14 | 21 | |
| 15 | 52 | |
| 16 | Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma. | 41 |
| 17 | 67 | |
| 18 | 55 | |
| 19 | 28 | |
| 20 | 28 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.